Literature DB >> 23904365

Role of brain-derived neurotrophic factor in bone marrow angiogenesis in multiple myeloma.

Zhang-Bo Chu1, Chun-Yan Sun1, Di Yang1, Lei Chen1, Yu Hu1.   

Abstract

This study examined the expression of brain-derived neurotrophic factor (BDNF) in multiple myeloma (MM) and its role in bone marrow angiogenesis. The peripheral blood plasma was harvested from 71 MM patients and 63 patients without hematological malignancy. The BDNF level in the blood plasma was determined by ELISA. Human bone marrow endothelial cells (HBMECs) were cultured. The mRNA and protein expression levels of the BDNF receptor TrkB in HBMECs were detected by using RT-PCR and flow cytometry, respectively. The viability of HBMECs treated with recombinant human (rh) BDNF or not was measured by using MTT assay. The migration of HBMECs in the presence of rhBDNF or not was determined by modified Boyden chamber assay. In vitro tube formation assay was used to assess the effect of rhBDNF on HBMECs differentiation. The results of ELISA revealed that the BDNF level was significantly higher in peripheral blood plasma of MM patients than in that of control patients (4.39±0.67 vs. 1.96±0.39 ng/mL, P<0.05). The BDNF receptor TrkB was expressed in HBMECs at mRNA and protein level. MTT assay manifested that rhBDNF could significantly concentration-dependently promote the HBMECs proliferation. The number of HBMECs treated with 160 ng/mL rhBDNF for 48 h was 1.57±0.10 folds higher than that in control group (P<0.05). Moreover, rhBDNF could enhance HBMECs migration in a concentration-dependent manner and the maximal migration was reached in the presence of 100 ng/mL rhBDNF. The migration indexes were 1.40±0.11, 1.64±0.16, 2.06±0.25 and 2.18±0.21 in 25, 50, 100 ng/mL rhBDNF groups and 25 ng/mL rhVEGF group, respectively. In vitro tube formation assay demonstrated that the area of the formed tubular structure was increased with the rhBDNF concentration. In control group, there was no formation of intact tubular structure and the HBMECs on the matrigel were irregularly dispersed. HBMECs treated with 100 ng/mL rhBDNF could form intact tubular structure and the area and the diameter of tubes were significantly greater than those in control group (P<0.05). There was no significant difference in the formed tubular area between 25 ng/mL VEGF group and 100 ng/mL rhBDNF group. It was concluded that BDNF plays an important role in myeloma cell-induced angiogenesis, and it may become a new target of anti-angiogenesis treatment for MM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904365     DOI: 10.1007/s11596-013-1146-3

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  27 in total

1.  Bone marrow angiogenesis and progression in multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Annunziata De Luisi; Arianna Ferrucci; Michele Moschetta; Angelo Vacca
Journal:  Am J Blood Res       Date:  2011-06-08

2.  In vitro endothelial cell susceptibility to xenobiotics: comparison of three cell types.

Authors:  B L'Azou; P Fernandez; R Bareille; M Beneteau; C Bourget; J Cambar; L Bordenave
Journal:  Cell Biol Toxicol       Date:  2005-03       Impact factor: 6.691

3.  Biological influence of brain-derived neurotrophic factor on breast cancer cells.

Authors:  Xiaomei Yang; Tracey A Martin; Wen G Jiang
Journal:  Int J Oncol       Date:  2012-08-06       Impact factor: 5.650

4.  Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma.

Authors:  Chi-Tat Lam; Zhen-Fan Yang; Chi-Keung Lau; Ka-Ho Tam; Sheung-Tat Fan; Ronnie T P Poon
Journal:  Clin Cancer Res       Date:  2011-03-18       Impact factor: 12.531

5.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

Authors:  Angelo Vacca; Roberto Ria; Domenico Ribatti; Fabrizio Semeraro; Valentin Djonov; Francesco Di Raimondo; Franco Dammacco
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

6.  Nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and glial-derived neurotrophic factor enhance angiogenesis in a tissue-engineered in vitro model.

Authors:  Mathieu Blais; Philippe Lévesque; Sabrina Bellenfant; François Berthod
Journal:  Tissue Eng Part A       Date:  2013-03-26       Impact factor: 3.845

7.  High-affinity neurotrophin receptors and ligands promote leukemogenesis.

Authors:  Zhixiong Li; Gernot Beutel; Mathias Rhein; Johann Meyer; Christian Koenecke; Thomas Neumann; Min Yang; Jürgen Krauter; Nils von Neuhoff; Michael Heuser; Helmut Diedrich; Gudrun Göhring; Ludwig Wilkens; Brigitte Schlegelberger; Arnold Ganser; Christopher Baum
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

Review 8.  Brain-derived neurotrophic factor: a newly described mediator of angiogenesis.

Authors:  Pouneh Kermani; Barbara Hempstead
Journal:  Trends Cardiovasc Med       Date:  2007-05       Impact factor: 6.677

9.  Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma.

Authors:  Yu Hu; Ya-dan Wang; Tao Guo; Wen-ning Wei; Chun-yan Sun; Lu Zhang; Jin Huang
Journal:  Cancer Genet Cytogenet       Date:  2007-10-01

10.  Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer.

Authors:  Y Okugawa; K Tanaka; Y Inoue; M Kawamura; A Kawamoto; J Hiro; S Saigusa; Y Toiyama; M Ohi; K Uchida; Y Mohri; M Kusunoki
Journal:  Br J Cancer       Date:  2012-11-22       Impact factor: 7.640

View more
  1 in total

1.  Brain-derived neurotrophic factor promotes immune reconstitution following radiation injury via activation of bone marrow mesenchymal stem cells.

Authors:  Guru Prasad Sharma; Anne C Frei; Jayashree Narayanan; Tracy Gasperetti; Dana Veley; Asma Amjad; Katherine Albano; Brian L Fish; Heather A Himburg
Journal:  PLoS One       Date:  2021-10-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.